(Oslo, June 5, 2023) Medistim ASA (OSE: MEDI), a global niche market leader in
ultrasound technology for medical use in Cardiac, Vascular and Transplant
surgery, is pleased to announce its partnership with ROMA-Women, a
groundbreaking cardiac surgery trial that is specifically focused on women.
Historically, cardiovascular research and treatment protocols have primarily
focused on men, leaving women underrepresented in clinical studies and
potentially receiving suboptimal care. Recognizing this disparity, Medistim has
joined forces with the trial to champion gender-specific healthcare
advancements. 

The multicenter randomized clinical trial, ROMA-Women, will enroll about 2,000
women, studying the use of single versus multiple arterial grafts in coronary
artery bypass (CABG) surgery.  The trial is spearheaded by renowned experts in
the field of cardiac surgery, including principal investigators Mario Gaudino,
Professor at Weill Cornell Medicine, USA, and Stephen Fremes, Professor at
Sunnybrook Health Sciences, Canada. More than 100 centers across the world are
expected to participate.  The trial is an extension of the ongoing ROMA trial
and has already enrolled about 700 women.  

ROMA-Women aims to address the unique cardiovascular needs and challenges faced
by women. Compared to men, women are referred for CABG at an older age and have
more frequently diabetes, hypertension, and dyslipidemia.  From a surgical
perspective, the CABG operation is generally more complex in women because of
smaller and more spastic coronary arteries than men.  Hence, it is believed that
graft assessment may be even more important in women, and in this trial, graft
patency will be assessed with Medistim's Transit Time Flow Measurement (TTFM)
and High Frequency Ultrasound (HFUS) technologies. 

"We are thrilled to collaborate with this pioneering cardiac surgery trial
exclusively dedicated to women," says Kari E. Krogstad, President and CEO at
Medistim. "In this trial, we will contribute with our expertise, resources, and
innovative technologies. At Medistim, we are passionate about advancing patient
care and empowering women in all parts of the patient care value chain. This
partnership not only aligns with our company culture but also embodies our
commitment to driving innovation and addressing the unmet needs of diverse
patient populations."

"We are very grateful to Medistim for the partnership and support. ROMA-Women
will not only improve women's health and outcomes after bypass surgery, but also
has the potential to revolutionize the approach to generating evidence in women
and patients who have traditionally not been adequately represented in clinical
trials. This is an enormous and ambitious effort, and we need all the help
possible - Medistim stepping in and being at our side is instrumental in the
success of the trial," says lead investigator Mario Gaudino.

About Medistim: Medistim is a pioneering MedTech company dedicated to improving
patient outcomes through innovation and advanced technology. With a deep-rooted
commitment to delivering patient-centered care, Medistim is transforming the
landscape by developing tailored solutions for diverse applications. Medistim
was established in 1984 and has a track record of profitable growth over the
past 20 years. Medistim has wholly owned subsidiaries with sales organizations
in the USA, Canada, China, Germany, the UK, Spain, Denmark, and Norway, in
addition to around 60 distributors in Europe, Asia, the Middle East, Africa, and
South America. 


For more information, contact:  
President and CEO, Kari E. Krogstad, Medistim ASA 
Tel: + 47 918 38 110   
Email: kari.krogstad@medistim.com  
CFO, Thomas Jakobsen, Medistim ASA 
Tel: + 47 906 59 940   
Email: thomas.jakobsen@medistim.com